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aim of this study was to identify outcomes in pain relief and quality of life in patients with a
solitary painful osseous metastasis treated by radiotherapy, cryoablation or the combination
using a propensity score matching study design.
Materials and Methods
175 patients with painful bone metastases were included in the study. Twenty-five of them
underwent a radiation course (20 Gy in five daily fractions) 15 days after the cryoablation.
These subjects were retrospectively matched by propensity analysis with a group of sub-
jects treated by radiotherapy (125 subjects) and with a group treated byCryoablation (25
subjects). The pain relief in terms of complete response, rate of subjects requiring analge-
sics after treatments and the changes in self-rated quality of life were measured. Informed
consent was obtained from the subject and the study was approved by the local Ethical
Committee.
Results
An higher proportion of subjects treated by cryoablation (32%) or cryoablation followed
by RT (72%;) experienced a complete response compared with patients treated by radio-
therapy alone (11.2%). After Bonferroni correction strategy, the addition of radiotherapy
to cryoablation significantly improved the rate of complete response compared with cryoa-
blation alone (p = 0.011) and this paralleled with an improved self-rated quality of life.
PLOS ONE | DOI:10.1371/journal.pone.0129021 June 23, 2015 1 / 11
OPEN ACCESS
Citation: Di Staso M, Gravina GL, Zugaro L, Bonfili
P, Gregori L, Franzese P, et al. (2015) Treatment of
Solitary Painful Osseous Metastases with
Radiotherapy, Cryoablation or Combined Therapy:
Propensity Matching Analysis in 175 Patients. PLoS
ONE 10(6): e0129021. doi:10.1371/journal.
pone.0129021
Editor: Shian-Ying Sung, Taipei Medical University,
TAIWAN
Received: January 14, 2015
Accepted: May 3, 2015
Published: June 23, 2015
Copyright: © 2015 Di Staso et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: The authors have no support or funding to
report.
Competing Interests: The authors have declared
that no competing interests exist.
Seventeen subjects (13.6%) of patients in the radiotherapy group, 9 (36%) in the cryoabla-
tion group, and 19 (76)% in the cryoablation- radiotherapy group did not require narcotic
medications.
Conclusions
The addition of radiotherapy to cryoablation favorably impacts on perceived pain, with a
favorable toxicity profile. However, our data should be interpreted with caution and could
serve as a framework around which to design future trials.
Introduction
Bone metastases are the main cause of cancer-associated death in patients with cancer [1] and
represent one of the most common sites of metastasis [2–3].Breast, prostate, and lung cancers
collectively represent the primary tumors that more frequently metastasize to bone [4]. Fur-
thermore, considering that a reduced bone matrix is found in patients suffering from breast
and prostate cancers treated with hormonal therapies, bone metastasis grows into a compart-
ment bone that is itself already weakened [5–6].
Among the potential complications related to bone metastasis, pain is the symptom most
frequently referred by patients [4] resulting in a drastic deterioration of their quality of life
(QoL) [1, 4, 5, 7, 8].For patients with overt bone metastases, current treatment objectives are
designed to decrease tumor burden, reduce skeletal-related events and maximize pain control
[5]. Current management of skeletal metastasis includes pain management/analgesia, systemic
therapy, radiation therapy (RT), surgery, and ablative techniques [9]. However, the long-term-
results of many of these treatment modalities may be not fully satisfying [10,11].
Thermoablation is a family of non-surgical approaches used to treat otherwise unrespect-
able tumors and using different power sources. Various delivery methods of ablation exist.
They include radiofrequency ablation (RFA), microwave ablation, high intensity focused ultra-
sound (HIFU), laser ablation, and cryoablation (CA) [12–14]. These techniques, initially devel-
oped for patients with malignant primary or metastatic liver tumors, have proven to be useful
therapeutic options for the management of bone tumors [15–18]. However, these ablative
approaches have rarely been used in combination in with RT [18]. Recently has been demon-
strated that the association of RFA with RT was well tolerated, with a satisfactory profile of
adverse events. [18–20]. In this study, for the first time, we investigated whether the sequential
addition of RT to CA could favorably affect clinical management of painful bone metastatic
lesions compared with CA and RT delivered as individual treatments.
Materials and Methods
Patient selection
In this study, patients older than 18 years with radiological and histological confirmed painful
solitary bone metastases were prospectively selected to undergo CA procedures followed by
RT. Magnetic resonance imaging (MRI) examination, computed tomography (CT), and
nuclear isotope (technetium 99) bone scan were planned within the 4 weeks prior to the proce-
dures. Other eligibility criteria included: (i) a pain score of 5 or more on the validated visual
analog scale (VAS) over the prior 24 hours (or a score of less than 5 with the use of narcotic
medications); (ii) pain localized to the site of the bone metastases; (iii) life expectancy of greater
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than 3 months; (iv) and Karnofsky performance status (KPS) score of greater than 70. Exclu-
sion criteria were: (i) a painful area previously treated with RT or palliative surgery; (ii) radio-
graphic evidence of spinal cord or cauda-equina compression; (iii) lesions positioned within
0.5 cm from a critical structure such as the spinal cord, brain, aorta, inferior vena cava, bowel,
or bladder; (iv) abnormal fracture of the treatment site.
The combined treatment was as arranged as follows: CA followed by RT 15 days later when
technically feasible. Between September 2011, and April 2014, 41 consecutive patients receiving
CA followed by RT were treated. Sixteen out of 41 subjects (39%) were excluded since (i)
refused to participate in the study (3/41; 7%), (ii) they did not satisfy the inclusion criteria (5/
41; 12.2%) and (ii) they did not match with any subject included in the groups treated by CA
or RT after propensity analysis (8/41; 19.5%). The group of patients undergoing the CA-RT
was retrospectively compared and matched by propensity analysis with a group of subjects
treated with RT or CA. The subjects included in RT or CA groups were retrospectively selected
from all who were treated in the Radiotherapy and Interventional Radiology units, respectively.
Analgesic consumption of all patients was recorded. Written informed consent was obtained
from the subject and the study was approved by the San Salvatore Hospital IRB (Deliberation
n. 89/2012)
Treatment procedures
RT was delivered by three-dimensional conformal technique with a dose of 20 Gy in five frac-
tions of 4 Gy over 1 week. Percutaneous cryotherapy ablation was carried out under conscious
sedation with an argon-based cryotherapy system (SEEDNET GOLD Cryoablation System,
Galil Medical LTD, Israel). After sterile preparation, one or more cryoprobes (ICEROD, Galil
Medical LTD, Israel) were introduced into the target lesion by CT guidance by experienced
radiologists. The cryoprobes were introduced in a parallel arrangement approximately 2 cm
apart. For larger lesions, a cluster of cryoprobes was placed within 1 cm of the tumor margin to
provide adequate coverage of the outer border of the target lesion. Cryoprobe positioning was
confirmed by CT imaging. Rapid freezing of the target lesion (-100°C within a few seconds)
was obtained and two 15-minute freezes separated by a 10-minute thaw were used at each cryo-
probe position. At the end of each procedure, CT was performed to ensure that the extent of
ablation was confined to the target tissue and that there was no substantial damage in the tissue
surrounding the target. After all combined procedures, patients were observed for 2 hours in
the recovery room and then were admitted to the hospital for a minimum of 24 hours.
Patient assessment
A full physical examination was performed and data on direct and indirect changes in pain lev-
els were assessed by VAS and medication level questionnaire. QoL was assessed with a single
question from the McGill Quality of Life Questionnaire (MQOL) [21].The strongest evidence
of validity comes from comparison with the single-item quality of life measure [21].
Study endpoints and response criteria
The primary endpoints were the percentage of patients with a (1) complete response (CR) at 12
weeks after treatments as previously described [22,23]. The secondary endpoints were (1) the
rate of subjects requiring analgesics at 12 weeks after treatments and (2) the changes in self-
experienced QoL. Complete response was defined as a pain score of 0 at treated site with no
concomitant increase in analgesic intake (stable or reducing analgesics in daily oral morphine
equivalent [OMED]). Partial response was defined as pain reduction of 2 or more at the treated
site on a scale of 0 to 10 scale without analgesic increase, or analgesic reduction of 25% or more
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from baseline without an increase in pain. Pain progression was defined as increase in pain
score of 2 or more above baseline at the treated site with stable OMED, or an increase of 25%
or more in OMED compared with baseline with the pain score stable or 1 point above baseline.
Stable-intermediate response was defined as any response that is not captured by the complete
response, partial response, or pain progression definitions.
Statistical analysis
The data analyzed in this report were derived from a population-based observational study. In
order to reduce treatment selection bias and determine realistically the treatment effects, a case
control-matched propensity analysis was performed. Pairwise nearest neighbor matching with
a caliper was used to minimized distance within matched sets applying a caliper of 0.1 on the
propensity score scale. Increasing the number of controls included in each matched set may
increase the precision of the estimated treatment effect. The optimum number of controls
needed to match to each treated subject may range from 1 to 5. Increasing the number of con-
trols matched to each treated subject will increase the size of the matched sample, resulting in
estimates of treatment effect with increased precision. Multivariate logistic regression was used
to calculate the predicted probability of the dependent variables as well as the propensity score
for all observations in the data set. The dependent variables included in the multivariate analy-
sis were age, KPS, primary tumors, anatomic site, VAS scale, and QoL before procedures. A 1:5
matched analysis was performed where one case (subject treated by CA or CA followed by RT)
was matched to five controls (subjects treated by RT).
The primary endpoint of this feasibility study was that, for patients with painful bone metas-
tasis, pain relief achieved following CA-RT in terms of CR should be higher than that achieved
following RT alone. The current study was powered to determine an increase of 21% or greater
in the CR at 12 weeks after CA-RT with respect to RT alone. The literature indicates that from
11 to 21% of intention-to-treat (ITT) patients achieved CR after RT [24]. Thus, we set the rate
of CR after RT at 11% (P0 = 11%). Using a two-sided test and a 5% type I error adjusted for
Bonferroni correction (p<0.0166), with the matched control to case ratio of 1:5, 25 subjects in
the experimental groups (CA group and CA-RT group) and 125 in the control group (RT)
would provide greater than 80% power to detect an increase of 21% (P1 = 32%).
Continuous variables not normally distributed (Shapiro-Wilk test) were presented as medi-
ans and 95% confidence intervals (95%CI). The Mann-Whitney U test was used to evaluate the
difference between two groups and Kruskal-Wallis test was used to evaluate the difference
among more than two tests. If the Kruskal-Wallis test was statistically significant, apairwise
comparison of subgroups was performed according to Conover. Dichotomous variables were
summarized by absolute and/or relative frequencies. The chi-squared test or Fisher’s exact test
was used to evaluate the difference between two groups. For multiple comparisons, the alpha
value threshold was adjusted by using Bonferroni correction. All tests were two-sided except
where specified and were determined by Monte Carlo significance. An alpha value threshold of
0.05 was used. All statistical analyses were performed using the SPSS statistical analysis soft-
ware package, version 10.0 (IBM Corporation 1 New Orchard Road, Armonk, New York
10504–1722 United States).
Results
Local pain control and self-perceived QoL
Table 1 lists the clinical and demographic characteristics of treated patients stratified according
to propensity score and treatment received. All subjects were valuable at the end point of 12
weeks. This was mainly due to the selection criteria (solitary bone lesion) which configure this
Cryotherapy and RT in Bone Metastases
PLOS ONE | DOI:10.1371/journal.pone.0129021 June 23, 2015 4 / 11
group of patients as long survivors. A higher proportion of subjects treated by CA (32% [8/25];
p = 0.018) or by CA followed by RT (72% [18/25]; p<0.0001) experienced a CR at 12 weeks
with respect to patients treated by RT alone (11.2% [14/125]; Table 2). Interestingly, the addi-
tion of RT to CA significantly improved the rate of CR with respect to CA used as individual
treatment (p = 0.011). A PR was more frequently observed in patients treated by RT (42.4%
[53/125]) or CA (36% [9/25]) with respect to subjects treated by CA followed by RT (12% [3/
25]) (Table 2).
The higher rate of CR observed in patients treated with CA followed RT with respect to
those treated with CA or RT paralleled an improved self-rated QoL (Fig 1). At 12 weeks,
patients treated by CA followed by RT reported a higher improvement in self-rated QoL
Table 1. Clinical characteristics according propensity score.
Characteristics RT (n = 125) CA-RT (n = 25) CA (n = 25) p value
Age, Y* 68 (66 to 69) 69 (65 to 71) 67.5 (64.4 to 70.6) 0. 0.454°
VAS Scale* 7 (6 to 7) 7 (6 to 8) 7.5 (5 to 7.6) 0.766°
Sex, No (%) 0.950°°
Male 61 (48.8) 13(52) 12(48)
Famale 64 (51.2) 12 (48) 13 (52)
KPS, No 0.908°*
91–100 64 (51.2) 12 (48) 11 (44)
70–89 61 (48.8) 13 (52) 14 (56)
Tumor Size, cm (longest diameter) 4 (4 to 5) 5 (4 to 5) 4 (3.4 to 6) 0.099°
Primary Tumors, No (%) 0.940°*
Lung Cancer 38 (30.4) 6 (24) 6 (24)
Prostate Cancer 41 (32.8) 8 (32) 8 (32)
Renal Cancer 9 (7.2) 2 (8) 4 (16)
Colorectal Cancer 8 (6.4) 2 (8) 2 (8)
Breast Cancer 29 (23.2) 7 (28) 5 (20)
Metastasis Location, No(%) 0.961°*
Pelvis 52 (41.6) 9 (36) 8 (32)
Sacrum 29 (23.2) 6 (24) 7 (28)
Rib 10 (8) 2 (8) 2 (8)
Vertebrae 22 (17.6) 4 (16) 4 (16)
Humerus 9 (7.2) 2 (8) 2 (8)
Femur 3 (2.4) 2 (8) 2 (8)
Characteristics RT (n = 125) CA-RT (n = 25) CA (n = 25) pvalue
Medical Systemic Treatments **
Bisphosphonates 35(28) 9 (36) 8 (32) 0.701°°
Narcotic Analgesics 125 (100) 25 (100) 25 (100) 1.0°*
HormonalTherapy 34 (27.2) 7 (28) 8 (32) 0.888°°
Chemotherapy 80 (64) 16 (64) 15 (60) 0.745°*
Immunotherapy 9 (7.2) 2 (8) 4 (12) 0.023°°
KPS = Karnofsky performance status
° Kruskal-Wallis test; Medians and CI95%
°* Chi Square test
°° Fisher’s Exact test; RT = radiotherapy; CA-RT = Cryoablation-Radiotherapy
**the sum of percentage in each group is over 100% since patients may perform more than one systemic treatment. In post hoc pairwise comparisons of
subgroups the alpha error was set at 0.016 according to Bonferroni correction.
doi:10.1371/journal.pone.0129021.t001
Cryotherapy and RT in Bone Metastases
PLOS ONE | DOI:10.1371/journal.pone.0129021 June 23, 2015 5 / 11
(MQOL score: 7, CI95% 5.4 to 9) with respect to subjects treated by RT alone (MQOL score: 5,
CI95% 4 to 5). At the same time, patients treated by CA alone experienced a significant
improvement of self-rated QoL (MQOL score: 6, CI95% 5 to 8) with respect to subjects treated
by RT alone (MQOL score: 5, CI95% 4 to 5) (Fig 1). Finally, although an improvement in the
self-rated QoL between CA and CA-RT was observed, the difference did not reach statistical
significance (Fig 1).
All patients received oral narcotic analgesic over the month before treatment with CA, RT,
or CA followed by RT (Table 1).In this regard, at 12 weeks, 13.6% of patients (17/125) in the
RT group, 36% of patients (9/25) in the CA group, and 76% of patients (19/25) in the CA-RT
group did not require narcotic medications (Table 3). This figures paralleled with the reduction
in the 24-hours median morphine-equivalent dose. Before treatments the 24-hours median
morphine-equivalent dose was 80 mg (95%CI 75–80) in the RT Group, 70 mg (95%CI 65–80)
in the CA Group and 80 mg (CI95% 65.7–80) in the CA+RT Group with no significant differ-
ence among groups (p = 0.67). A significant decrease in the 24-hours median morphine-equiv-
alent dose at week 12 was documented in the CA (p = 0.008) and CA-RT (p = 0.004) groups
with respect to the RT group (Table 3). Overall, patients tolerated the CA and combined treat-
ments well. Forty (80%) out of the 50 patients performed CA without complications. The com-
plications were listed in Table 4.
Discussion
Radiation treatment is one of the most important non-surgical approaches for the management
of osteolytic or osteosclerotic bone lesions [25] with sub-optimal overall response rate [25].
Table 2. Response rate following Radiotherapy vs Cryoablation vs Cryoablation combined with Radiotherapy at 12 weeks.





Complete response (No, %) 14/125
(11.2)
8/25 (32) 18/25 (72) CA vs RT p = 0.018CA vs CA-RT p = 0.011 CA-RT vs RT
p<0.0001
Partial Response (No,%) 53/125
(42.4)
9/25 (36) 3/25 (12) CA vs RT p = 0.711CA vs CA-RT p = 0.098 CA-RT vs RT
p = 0.008




8/25 (32) 4/25 (16) CA vs RT p = 0.270CA vs CA-RT p = 0.321CA-RT vs RT p = 0.009
°Chi Square testor Fisher exact test. In post hoc pairwise comparisons of subgroups the alpha error was set at 0.016 according to Bonferroni correction;
RT = radiotherapy; CA-RT = Cryoablation-Radiotherapy;
doi:10.1371/journal.pone.0129021.t002
Fig 1. Quality of life score measured by single question fromMQOL. Self ratedQoL before (A) and after
treatments (B).
doi:10.1371/journal.pone.0129021.g001
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Interventional radiologists developed different ablative approaches, which demonstrated out-
standing effects in terms of clinical efficacy in a wide range of clinical scenarios including bone
metastatic disease. However, a number of patients may respond unsatisfactorily to these treat-
ments in terms of pain control. Recently, the management of painful bone metastases was
effectively achieved by combining ionizing radiation with RFA [18–20]. These encouraging
preliminary results induced us to study if the addition of RT to CA would result in improved
clinical efficacy. To our knowledge, no existing empirical study has addressed the question of
whether percutaneous CT-based CA followed by RT achieves better pain control and improved
self-rated QoL than CA or RT delivered as individual treatments in the management of osteoly-
tic and/or mixed painful bone lesions. It is well-known that the localization of the bony metas-
tases may affect the way subjects perceived their symptoms. This is an important
methodological point since an heterogeneity the localization of the bony metastases may con-
figure as a study bias. This bias was overcome by using propensity analysis and a balance
among groups for this variable was achieved. Cryotherapy is a well-known ablative technique
which, thanks to new miniaturized argon-gas devices, creates an “ice-ball” deep in bone, with
less peri- and post-procedural pain. Callstrom and co-workers described the results of clinical
trials in which percutaneous CA was used for the palliation of painful metastatic lesion [26–
27]. Interestingly, they found that CA was an effective and safe way for palliation of pain
related to metastatic lesions. Although authors did not specifically investigate this issue, they
found that 62% of studied subjects received RT course prior to CA [27]. In these subjects no
improvement in pain response with respect to subjects who did not perform RT was found
[27]. In contrast, we found that when RT was delivered after CA, it favorably impacted on pain
control in subjects with painful bone lesions. The main methodological difference with Call-
strom’s study is that in ours, the radiation course was added sequentially to CA. The temporal
sequence of two treatments was based on the hypothesis that RT may improve CA efficacy.
Table 3. Post-treatment narcotic analgesic use andmorphine equivalent dose at 12 weeks.















°°CA vs RT p = 0.008 °°CA vs CA-RT p = 0.71°°CA-RT vs RT
p = 0.004
°Chi Square test; RT = radiotherapy; CA-RT = Cryoablation-Radiotherapy
°°Kruskal Wallis test with post hoc pairwise comparison of subgroups performed according to Conover
°* median and CI95%.
doi:10.1371/journal.pone.0129021.t003





Complications Clinical outcome and treatment
5/50 (10%) Sacrum Injury to encased sacral
plexus
Gluteal, perineal, and thigh numbness resolved by corticosteroid treatment
approximately 3 weeks after cryoablation
2/50 (4%) Vertebrae Transient injury to adjacent
peripheral nerve
Resolved by corticosteroid treatment approximately 2 weeks after cryoablation
2/50 (4%) Pelvis Injury to encased sacral
plexus
Gluteal, perineal, and thigh numbness resolved by corticosteroid treatment
approximately 3 weeks after cryoablationInfection at the access site managed
by percutaneous drainage and antibiotic treatment
1/50 (2%) Humerus Humerus fracture Resolved by conservative approach
doi:10.1371/journal.pone.0129021.t004
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Recent studies have reported achieving a synergistically increased rates of survival and tumor
local control in both animal models and in patients with stage I lung cancer, when RFA was fol-
lowed by RT [28–34]. We know that RT efficacy is largely dependent on tissue oxygenation,
whereas this biological parameter does not influence CA efficacy. Bone lesions have a hypoxic
microenvironment in their inner cores and CA, whose effectiveness is largely independent of
tumor oxygen content, may effectively kill hypoxic centrally located tumor cells. In contrast,
the outer ring contains fewer hypoxic tumor cells on which RT can effectively exert its cyto-
toxic effect. Additionally, it is possible that perturbation of the tumor microenvironment after
ablation may improve the efficacy of subsequent RT on the malignant tissue [35]. However, the
exact mechanisms through which CA followed by RT may relieve symptomatic pain remains
largely unknown.
The pain experienced by subjects suffering from bone metastases may have several patho-
physiologal mechanisms, including: (i) microfractures by direct metastatic bone invasion; (ii)
periosteum distortion due to increased pressure on the endosteum; (iii) nerve-root compres-
sion or muscle spasm; and (iv) release of chemical mediators involved in the conduction of
nociceptive impulses to the central nervous system [2,3]. The decrease of cancerous cell burden
within bone tissue associated with a lowering of endosteum pressures and modification of the
release of pain-related chemical mediators related with the combinational treatment may sub-
stantially influence the perception of pain intensity.
The improvement of CR rate we found, in terms of pain control, showed that 11.2% of sub-
jects treated by RT achieved a CR. The rate of CR was significantly improved with respect to
RT in subjects treated by CA (32%) and interestingly, when RT was sequentially added to CA,
the percentage of patients achieving a CR was 72%. These data paralleled the improvement of
self-rated QoL observed in subjects treated by CA and CA followed by RT with respect to sub-
jects treated by RT alone. When RT was sequentially added to CA the subjects experienced
improved QoL, although the difference did not reach statistical significance.
In terms of medical adjunctive treatment, all subjects took narcotic medications before
treatments. At 12 weeks post treatment, 13.6% of patients in the RT group, 36% in the CA
group, and 76% in the CA-RT group did not require narcotic medications and the 24-hour
median morphine-equivalent dose significantly decreased with respect to baseline, with the
major decrease found after CA or CA followed by RT. Finally, although the rate of complica-
tions we reported seems to be higher than that reported by Calstrom [20], the combinational
treatment was well tolerated since 84% of patients were ablated without complications. The
recorded complications were all transient and none of treaded subject presented irreversible
injures at 12 weeks after treatments.
Several limitations affect our study. The main ones are the sample size and the use of a non-
randomized study design. To date, large randomized controlled trials (RCT) have provided the
strongest evidence for the efficacy of therapeutic procedures or treatments in the clinical set-
ting. However, this bias has been mitigated by the use of a strategy based on propensity score
analysis, which helped us to obtain groups of patients randomized post-hoc for important clin-
ical characteristics. Thus, comparative analysis by propensity-matched pairs contributed to the
results being less prone to methodological biases than other usual statistical methods. Finally,
the positive results obtained in terms of both QoL and pain control may be partially imputable
to the adjunctive oncological medical treatments that the subjects included in this study per-
formed concomitantly with RT, CA and CA+RT. If these medical treatments have contributed
to the effects measured in this study is unclear. In this regard, a strategy of assessment based on
the measurement of outcome measures before the start of adjunctive oncological medical treat-
ments may not ensure that the pain or the QoL perceived at that moment may be similar to
that experienced when RT, CA or CA+RT was then effectively delivered. This situation is
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imputable to the fact that these medical treatments may go on for several weeks and during
this time period the symptoms may profoundly change. However, we believe of having mini-
mized this issue by adopting the propensity score analysis. In this regard the percentage of sub-
jects using oncological systemic adjuvant treatments did not significantly differ across the
groups making the confounding effect of this variable on outcome measure balanced in the
groups. So, if we reasonably assume that at the time of local treatment with RT, CA or CA+RT
the rate and the type of oncological medical treatments were comparable across the groups any
improvement measured in pain or QoL was imputable to the aforementioned local treatments.
Different may be the question concerning the fact if one or more of these oncological medical
treatments may have potentiated the effects of RT, CA or CA+RT. It is very difficult to answer
to this question since we cannot be sure which treatment is responsible for the enhancement of
local treatments effects. All these reasons make our conclusions not equally generalizable to the
population of patients suffering from solitary painful bone metastases who are both treated or
not treated with multimodal oncological medical treatments. It is our opinion that the results
here described are better suitable for the larger population of patients who is actively treated
with multimodal oncological medical treatments.
Despite these methodological limitations our data seem to suggest, for the first time, that
the addition of sequential RT to CA favorably impacts on the pain of painful bone metastases.
However our results have to be interpreted with caution and to serve as a framework around
which to design future large-scale RCT.
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